Antoni Castro

Prof. Dr. Antoni Castro

orcid

Research Focus & Metrics

Academic Career Length

35Years (1992-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2018 in Clinical Nutrition
Verified
Journal Article
Closed access
NBNerea Becerra-Tomás
Nerea Becerra-Tomás
ADAndrés Díaz-López
Andrés Díaz-López
NRNúria Rosique-Esteban
Núria Rosique-Esteban
EREmilio Ros
Emilio Ros
PBPilar Buil-Cosiales
Pilar Buil-Cosiales
JTJ. Timiraus-Fernández
J. Timiraus-Fernández

1 September 2017 in Annals of the Rheumatic Diseases
Verified
Journal Article
Closed access
PDF file
JOJosep Ordi-Ros
Josep Ordi-Ros
LSLuis Sáez-Comet
Luis Sáez-Comet
MPMercedes Pérez-Conesa
Mercedes Pérez-Conesa
XVXavier Vidal
Xavier Vidal
FMFrancesca Mitjavila
Francesca Mitjavila
JCJosefina Cortés-Hernández
Josefina Cortés-Hernández
Objective To compare the efficacy and safety of enteric-coated mycophenolate sodium (EC-MPS) versus azathioprine (AZA) in patients with active systemic lupus erythematosus (SLE) disease. Methods A multicentre, 24-month, superiority, open-label, randomised controlled trial (NCT01112215) was conducted with 240 patients (120 per arm) receiving either EC-MPS (target dose: 1440 mg/day) or AZA (target dose: 2 mg/kg/day) in addition to prednisone and/or antimalarials. The primary endpoint was the proportion of patients achieving clinical remission, assessed by SLE Disease Activity Index 2000 (SLEDAI-2K) and British Isles Lupus Assessment Group (BILAG), at 3 and 24 months. Secondary endpoints included time to clinical remission, BILAG A and B flare rates, time to flare, corticosteroid reduction and adverse events (AEs). Results Proportion of patients achieving clinical remission (clinical SLEDAI=0) was higher in the EC-MPS group at 3 (32.5% vs 19.2%; treatment difference, 13.3 (CI 2.3 to 24), p=0.034) and 24 months (71.2% vs 48.3%; treatment difference, 22.9 (CI 10.4 to 34.4), p<0.001). EC-MPS was superior with respect to time to clinical remission (HR 1.43; 95% CI 1.07 to 1.91; p=0.017). BILAG A/B and B flares occurred more frequently in the AZA group (71.7% vs 50%, p=0.001 and 21.67% vs 8.3%, p=0.004, respectively). EC-MPS was superior with respect to time to first BILAG A/B (HR 1.81; 95% CI 1.3 to 2.56; p=0.0004) and BILAG A flare (HR 2.84; 95% CI 1.37 to 5.89; p=0.003). AEs were similar in both groups except for leucopenia that occurred more frequently with AZA. Conclusions EC-MPS was superior to AZA in treating SLE and preventing further relapses. Trial registration number NCT01112215; Results.

6 September 2016 in Lupus Science & Medicine
Verified
Journal Article
Open access
PDF file
MRMonica Rydén-Aulin
Monica Rydén-Aulin
DBDimitrios Boumpas
Dimitrios Boumpas
IBIrene Bultink
Irene Bultink
JRJose Luis Callejas Rubio
Jose Luis Callejas Rubio
LCLuis Caminal-Montero
Luis Caminal-Montero
RVRonald van Vollenhoven
Ronald van Vollenhoven
Objectives Rituximab (RTX) is a biological treatment used off-label in patients with systemic lupus erythematosus (SLE). This survey aimed to investigate the off-label use of RTX in Europe and compare the characteristics of patients receiving RTX with those receiving conventional therapy. Methods Data on patients with SLE receiving RTX were taken from the International Registry for Biologics in SLE retrospective registry and complemented with data on patients with SLE treated with conventional therapy. For nationwide estimates of RTX use in patients with SLE, investigators were asked to provide data through case report forms (CRFs). Countries for which no data were submitted through CRFs, published literature and/or personal communication were used, and for European countries where no data were available, estimates were made on the assumption of similarities with neighbouring countries. Results The estimated off-label use of RTX in Europe was 0.5%–1.5% of all patients with SLE. In comparison with patients with SLE on conventional therapy, patients treated with RTX had longer disease duration, higher disease activity and were more often treated with immunosuppressives. The most frequent organ manifestations for which either RTX or conventional therapy was initiated were lupus nephritis followed by musculoskeletal and haematological. The reason for treatment was, besides disease control, corticosteroid-sparing for patients treated with conventional therapy. Conclusions RTX use for SLE in Europe is restrictive and appears to be used as a last resort in patients for whom other reasonable options have been exhausted.

1 March 2010 in Atherosclerosis
Verified
Journal Article
Closed access
ACAntoni Castro
Antoni Castro
ILIOLANDA LAZARO
IOLANDA LAZARO
DSDavid M. Selva
David M. Selva
ECEla Céspedes
Ela Céspedes
JGJosefa Girona-Tell
Josefa Girona-Tell
LMLluís Masana
Lluís Masana

1 March 1995 in Clinical Immunology and Immunopathology
Verified
Journal Article
Closed access
JPJ.M. Porcel
J.M. Porcel
JOJ. Ordi
J. Ordi
ACAntoni Castro
Antoni Castro
MVM. Vilardell
M. Vilardell
MRM.J. Rodrigo
M.J. Rodrigo
DVD. Vergani
D. Vergani

1 September 2017 in Clinical Biochemistry
Verified
Journal Article
Closed access
Jordi CampsJordi Camps
Jordi Camps
SISimona Iftimie
Simona Iftimie
AGAnabel García-Heredia
Anabel García-Heredia
ACAntoni Castro
Antoni Castro
JJJorge Joven
Jorge Joven